{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:04:11Z","timestamp":1773155051254,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Anti-tumour necrosis factor-alpha (TNF-\u03b1) agents are often used for Beh\u00e7et\u2019s disease (BD) in clinical practice, but they have not been validated by a high level of evidence. We systematically reviewed published controlled trials to investigate the efficacy and safety of anti-TNF-\u03b1 therapy and summarize the efficacy of anti-TNF-\u03b1 therapy relative to the available therapeutic options.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic database search was conducted (PubMed, Embase and Cochrane) using specific search terms. All controlled studies of anti-TNF-\u03b1 treatment of BD patients prior to December 2021 were included. Single-arm studies were excluded. The decision of whether to incorporate data into the meta-analysis or summarize the data by qualitative synthesis was based on the results of the literature screening.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of 4389 screened studies, 13 (total 778 patients) were included in accordance with our retrieval strategy, comprising 1 randomized controlled trial, 1 prospective study, 10 retrospective studies, and 1 multicentre open-label study. Ten studies (76.9%) involved Beh\u00e7et\u2019s uveitis (BU), 1 involved intestinal BD, and the other studies had undefined subtypes. Subgroup reviews were conducted according to the control drug. Four studies involving 167 participants reported relapse rates. Meta-analysis of three of these studies demonstrated that, compared with traditional immunosuppressant (TIS) therapy, anti-TNF-\u03b1 therapy reduced the relapse rates in patients with BU. In targeted drug comparison studies, the efficacy appeared to be similar between the anti-TNF-\u03b1 agent and interferon in BU patients. The rates of adverse events were comparable between a variety of different therapeutic controls. Serious adverse events were not observed in 53.8% (7\/13) of the studies.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Compared with TIS therapy, anti-TNF-a therapy reduces the relapse of uveitis in patients with BD. However, the evidence regarding anti-TNF-\u03b1 therapy is very limited for the full spectrum of BD subtypes, which calls for caution.<\/jats:p>","DOI":"10.3389\/fphar.2022.912906","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T15:43:11Z","timestamp":1660923791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with beh\u00e7et\u2019s disease: A systematic review of controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Xinwei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3346\/jkms.2017.32.1.33","article-title":"Polymorphisms of promoter region of TNF-\u03b1 gene in iranian azeri turkish patients with beh\u00e7et's disease","volume":"32","author":"Abdolmohammadi","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/35021228","article-title":"Toll-like receptors in the induction of the innate immune response","volume":"406","author":"Aderem","year":"2000","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: Receptors, functions, and roles in diseases.","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for behcet\u2019s disease: Analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to beh\u00e7et's disease: National multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1756-185X.12691","article-title":"Adult behcet's disease in Iran: analysis of 6075 patients","volume":"19","author":"Davatchi","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","article-title":"Effectiveness of infliximab and interferon alpha-2a for the treatment of beh\u00e7et's uveitis: customizing therapy according to the clinical features","volume":"30","author":"De Simone","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Behcet\u2019s disease: new insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00281-015-0502-8","article-title":"Pathogenesis of beh\u00e7et\u2019s disease: Autoinflammatory features and beyond","volume":"37","author":"G\u00fcl","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B12","volume-title":"Cochrane Handbook for systematic review of interventions","author":"Higgins","year":"2011"},{"key":"B13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in behcets' disease-associated uveitis: a systematic review and meta-analysis","volume":"24","author":"Hu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in Autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"iii108","DOI":"10.1093\/rheumatology\/keaa086","article-title":"Management of Behcet's syndrome","volume":"1","author":"Karadag","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jfo.2019.02.002","article-title":"Eye and beh\u00e7et's disease","volume":"42","author":"Ksiaa","year":"2019","journal-title":"J. Fr. Ophtalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3129\/i08-080","article-title":"Beh\u00e7et's disease: Comparing 3 decades of treatment response at the national eye Institute.","volume":"43","author":"Kump","year":"2008","journal-title":"Can. J. Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","article-title":"Anti-TNF-\u03b1 therapy for refractory uveitis associated with beh\u00e7et's syndrome and sarcoidosis: a single center study of 131 patients","volume":"30","author":"Kunimi","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","article-title":"Adalimumab for the treatment of uveitis","volume":"13","author":"LaMattina","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","article-title":"Beh\u00e7et's disease: An overview of etiopathogenesis","volume":"10","author":"Leccese","year":"2019","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","article-title":"Etanercept in the treatment of intestinal Behcet's disease","volume":"69","author":"Ma","year":"2014","journal-title":"Cell biochem. Biophys."},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatol. Oxf."},{"key":"B23","first-page":"98","article-title":"Short-term trial of etanercept in beh\u00e7et's disease: A double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.intimp.2013.07.017","article-title":"Possible mechanisms of neutrophil activation in Beh\u00e7et's disease","volume":"17","author":"Neves","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e12973","DOI":"10.1111\/sji.12973","article-title":"Beh\u00e7et disease (BD) and BD-like clinical phenotypes: NF-\u03baB pathway in mucosal ulcerating diseases","volume":"92","author":"Perazzio","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.17116\/oftalma2021137051130","article-title":"Beh\u00e7et's disease and uveitis","volume":"137","author":"Razumova","year":"2021","journal-title":"Vestn. Oftalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor necrosis factor \u03b1 and regulatory T cells in oncoimmunology","volume":"12","author":"Salomon","year":"2018","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of behcet's disease","volume":"29","author":"Tong","year":"2019","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-tnf alpha in severe and\/or refractory beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1093\/rheumatology\/keaa251","article-title":"Leukocyte toll-like receptor expression in pathergy positive and negative Beh\u00e7et's disease patients","volume":"59","author":"Van der Houwen","year":"2020","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the treatment results for beh\u00e7et uveitis in patients treated with infliximab and interferon","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"609148","DOI":"10.3389\/fphar.2021.609148","article-title":"The efficacy of adalimumab as an initial treatment in patients with beh\u00e7et's retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","article-title":"Comparative study of adalimumab versus conventional therapy in sight-threatening refractory beh\u00e7et's uveitis with vasculitis","volume":"93","author":"Yang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.revmed.2013.10.011","article-title":"Ocular manifestations in Beh\u00e7et's disease","volume":"35","author":"Zeghidi","year":"2014","journal-title":"Rev. Med. Interne"},{"key":"B38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/jgh.15754","article-title":"The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis","volume":"37","author":"Zhang","year":"2022","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.912906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T15:43:17Z","timestamp":1660923797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.912906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":39,"alternative-id":["10.3389\/fphar.2022.912906"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.912906","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"article-number":"912906"}}